Top

Published in:

01-01-2020 | Systemic Therapy | Head and Neck Cancer (CP Rodriguez, Section Editor)

Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment

Authors: Mayur D. Mody, MD, Nabil F. Saba, MD, FACP

Published in: Current Treatment Options in Oncology | Issue 1/2020

Opinion statement

Sinonasal malignancies pose a significant challenge in management due to their low incidence, biologic diversity, and significant symptom burden. Even though surgery remains the primary therapeutic modality, a multi-modality approach has been shown to benefit a significant proportion of patients and its success depends largely on stage and histologic type. Non-surgical approaches such as novel radiation approaches as well as intensification with systemic therapy hold promise in altering the organ preservation rate as well as overall survival for patients. Practice changing randomized trials to test these novel modalities are overdue and desperately needed.

Roush GC. Epidemiology of cancer of the nose and paranasal sinuses: current concepts. Head Neck Surg. 1979;2(1):3–11.CrossRef

Muir CS, Nectoux J. Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses. Clin Otolaryngol Allied Sci. 1980;5(3):195–211.CrossRef

Maghami E, Kraus DH. Cancer of the nasal cavity and paranasal sinuses. Expert Rev Anticancer Ther. 2004;4(3):411–24. https://doi.org/10.1586/14737140.4.3.411.CrossRefPubMed

Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34(6):877–85. https://doi.org/10.1002/hed.21830.CrossRefPubMed

Zheng W, McLaughlin JK, Chow WH, Chien HT, Blot WJ. Risk factors for cancers of the nasal cavity and paranasal sinuses among white men in the United States. Am J Epidemiol. 1993;138(11):965–72. https://doi.org/10.1093/oxfordjournals.aje.a116816.CrossRefPubMed

El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2005;29(10):1367–72.CrossRef

Bhattacharyya N. Factors affecting survival in maxillary sinus cancer. J Oral Maxillofac Surg. 2003;61(9):1016–21. https://doi.org/10.1016/s0278-2391(03)00313-6.CrossRefPubMed

Torjussen W. Occupational nasal cancer caused by nickel and nickel compounds. Rhinology. 1985;23(2):101–5.PubMed

Luce D, Leclerc A, Morcet JF, Casal-Lareo A, Gerin M, Brugere J, et al. Occupational risk factors for sinonasal cancer: a case-control study in France. Am J Ind Med. 1992;21(2):163–75.CrossRef

10.

Schwaab G, Julieron M, Janot F. Epidemiology of cancers of the nasal cavities and paranasal sinuses. Neurochirurgie. 1997;43(2):61–3.PubMed

11.

Devaraja K, Sikka K, Kumar R, Thakar A. Sinonasal malignancies: long term follow up after surgical management-an analysis of outcomes. Indian J Otolaryngol Head Neck Surg. 2015;67(1):28–33. https://doi.org/10.1007/s12070-014-0742-2.CrossRefPubMed

12.

Dulguerov P, Allal AS. Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg. 2006;14(2):67–72. https://doi.org/10.1097/01.moo.0000193177.62074.fd.CrossRefPubMed

13.

Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. Bmj. 2002;325(7368):822–7. https://doi.org/10.1136/bmj.325.7368.822.CrossRefPubMedPubMedCentral

14.

Ansa B, Goodman M, Ward K, Kono SA, Owonikoko TK, Higgins K, et al. Paranasal sinus squamous cell carcinoma incidence and survival based on surveillance, epidemiology, and end results data, 1973 to 2009. Cancer. 2013;119(14):2602–10. https://doi.org/10.1002/cncr.28108.CrossRefPubMed

15.

Carlton DA, David Beahm D, Chiu AG. Sinonasal malignancies: endoscopic treatment outcomes. Laryngoscope Investig Otolaryngol. 2019;4(2):259–63. https://doi.org/10.1002/lio2.249.CrossRefPubMedPubMedCentral

16.

• Husain Q, Joshi RR, Cracchiolo JR, Roman BR, Ganly I, Tabar V, et al. Surgical management patterns of sinonasal malignancy: a population-based study. J Neurol Surg B Skull Base. 2019;80(4):371–9. https://doi.org/10.1055/s-0038-1675233 Assessment of over 10,000 patients from National Cancer Data Base showing sinonasal cancers managed with endoscopic surgery had comparable outcomes to open resection.CrossRefPubMed

17.

Nicolai P, Battaglia P, Bignami M, Bolzoni Villaret A, Delu G, Khrais T, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol. 2008;22(3):308–16. https://doi.org/10.2500/ajr.2008.22.3170.CrossRefPubMed

18.

Higgins TS, Thorp B, Rawlings BA, Han JK. Outcome results of endoscopic vs craniofacial resection of sinonasal malignancies: a systematic review and pooled-data analysis. Int Forum Allergy Rhinol. 2011;1(4):255–61. https://doi.org/10.1002/alr.20051.CrossRefPubMed

19.

Wellman BJ, Traynelis VC, McCulloch TM, Funk GF, Menezes AH, Hoffman HT. Midline anterior craniofacial approach for malignancy: results of en bloc versus piecemeal resections. Skull Base Surg. 1999;9(1):41–6. https://doi.org/10.1055/s-2008-1058171.CrossRefPubMedPubMedCentral

20.

Lango MN, Topham NS, Perlis CS, Flieder DB, Weaver MW, Turaka A, et al. Surgery in the multimodality treatment of sinonasal malignancies. Curr Probl Cancer. 2010;34(5):304–21. https://doi.org/10.1016/j.currproblcancer.2010.07.001.CrossRefPubMed

21.

Sayed Z, Migliacci JC, Cracchiolo JR, Barker CA, Lee NY, McBride SM, et al. Association of surgical approach and margin status with oncologic outcomes following gross total resection for sinonasal melanoma. JAMA Otolaryngol Head Neck Surg. 2017;143(12):1220–7. https://doi.org/10.1001/jamaoto.2017.2011.CrossRefPubMedPubMedCentral

22.

Varelas AN, Eggerstedt M, Ganti A, Tajudeen BA. Epidemiologic, prognostic, and treatment factors in sinonasal diffuse large B-cell lymphoma. Laryngoscope. 2019;129(6):1259–64. https://doi.org/10.1002/lary.27639.CrossRefPubMed

23.

Goepfert H. The vex and fuss about nasal vestibule cancer. Head Neck. 1999;21(5):383–4.CrossRef

24.

Thorup C, Sebbesen L, Dano H, Leetmaa M, Andersen M, Buchwald C, et al. Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995–2004. Acta Oncol. 2010;49(3):389–94. https://doi.org/10.3109/02841860903428176.CrossRefPubMed

25.

Wang K, Zanation AM, Chera BS. The role of radiation therapy in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin N Am. 2017;50(2):419–32. https://doi.org/10.1016/j.otc.2016.12.014.CrossRef

26.

Huang D, Xia P, Akazawa P, Akazawa C, Quivey JM, Verhey LJ, et al. Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003;56(1):158–68. https://doi.org/10.1016/s0360-3016(03)00080-4.CrossRefPubMed

27.

Dirix P, Vanstraelen B, Jorissen M, Vander Poorten V, Nuyts S. Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(4):998–1004. https://doi.org/10.1016/j.ijrobp.2009.09.067.CrossRefPubMed

28.

Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014;15(9):1027–38. https://doi.org/10.1016/s1470-2045(14)70268-2.CrossRefPubMed

29.

Ghorbani M, Jia SB, Khosroabadi M, Sadoughi HR, Knaup C. Evaluation of the effect of soft tissue composition on the characteristics of spread-out Bragg peak in proton therapy. J Cancer Res Ther. 2017;13(6):974–80. https://doi.org/10.4103/0973-1482.220420.CrossRefPubMed

30.

van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist. 2011;16(3):366–77. https://doi.org/10.1634/theoncologist.2010-0171.CrossRefPubMedPubMedCentral

31.

• Dagan R, Bryant C, Li Z, Yeung D, Justice J, Dzieglewiski P, et al. Outcomes of Sinonasal Cancer treated with proton therapy. Int J Radiat Oncol Biol Phys. 2016;95(1):377–85. https://doi.org/10.1016/j.ijrobp.2016.02.019 Single institution review from the University of Florida analyzing disease outcomes after proton therapy for sinonasal cancer.CrossRefPubMed

32.

• Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, et al. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2016;95(1):368–76. https://doi.org/10.1016/j.ijrobp.2016.02.042 Single institution review from Massachusetts General Hospital reporting data on long-term outcomes in patients with sinonasal squamous cell carcinoma treated with proton therapy.CrossRefPubMed

33.

Zenda S, Kohno R, Kawashima M, Arahira S, Nishio T, Tahara M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2011;81(5):1473–8. https://doi.org/10.1016/j.ijrobp.2010.08.009.CrossRefPubMed

34.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43. https://doi.org/10.1200/jco.2013.54.6309.CrossRefPubMedPubMedCentral

35.

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704. https://doi.org/10.1056/NEJMoa071028.CrossRefPubMed

36.

LoRusso P, Tapazoglou E, Kish JA, Ensley JF, Cummings G, Kelly J, et al. Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. Cancer. 1988;62(1):1–5. https://doi.org/10.1002/1097-0142(19880701)62:1<1::aid-cncr2820620102>3.0.co;2-f.CrossRefPubMed

37.

Bjork-Eriksson T, Mercke C, Petruson B, Ekholm S. Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study. Cancer. 1992;70(11):2615–20. https://doi.org/10.1002/1097-0142(19921201)70:11<2615::aid-cncr2820701108>3.0.co;2-g.CrossRefPubMed

38.

Hanna EY, Cardenas AD, DeMonte F, Roberts D, Kupferman M, Weber R, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg. 2011;137(1):78–81. https://doi.org/10.1001/archoto.2010.231.CrossRefPubMed

39.

Hoffmann TK. Systemic therapy strategies for head-neck carcinomas: current status. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;11:Doc03. https://doi.org/10.3205/cto000085.CrossRefPubMedPubMedCentral

40.

Lee MM, Vokes EE, Rosen A, Witt ME, Weichselbaum RR, Haraf DJ. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999;5(4):219–23.PubMed

41.

Licitra L, Locati LD, Cavina R, Garassino I, Mattavelli F, Pizzi N, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol. 2003;14(3):367–72. https://doi.org/10.1093/annonc/mdg113.CrossRefPubMed

42.

Mendenhall WM, Amdur RJ, Morris CG, Kirwan J, Malyapa RS, Vaysberg M, et al. Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope. 2009;119(5):899–906. https://doi.org/10.1002/lary.20196.CrossRefPubMed

43.

Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol. 2007;33(2):222–8. https://doi.org/10.1016/j.ejso.2006.10.033.CrossRefPubMed

44.

Kang JH, Cho SH, Kim JP, Kang KM, Cho KS, Kim W, et al. Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis. J Oral Maxillofac Surg. 2012;70(7):1717–23. https://doi.org/10.1016/j.joms.2011.06.221.CrossRefPubMed

45.

Kim JH, Lee YS, Chung YS, Jang YJ, Kim SB, Lee SW, et al. Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: a single-institution study. Acta Otolaryngol. 2015;135(11):1189–95. https://doi.org/10.3109/00016489.2015.1061697.CrossRefPubMed

46.

Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2008;72(3):763–9. https://doi.org/10.1016/j.ijrobp.2008.01.038.CrossRefPubMed

47.

Resto VA, Chan AW, Deschler DG, Lin DT. Extent of surgery in the management of locally advanced sinonasal malignancies. Head Neck. 2008;30(2):222–9. https://doi.org/10.1002/hed.20681.CrossRefPubMed

48.

Chen NX, Chen L, Wang JL, Wang JY, Yan F, Ma L, et al. A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus. Jpn J Clin Oncol. 2016;46(8):727–34. https://doi.org/10.1093/jjco/hyw064.CrossRefPubMed

49.

Danesh-Sani SA, Sarafraz A, Chamani M, Derakhshandeh H. Paranasal sinuses malignancies: a 12-year review of clinical characteristics. Med Oral Patol Oral Cir Bucal. 2016;21(5):e626–30. https://doi.org/10.4317/medoral.21170.CrossRefPubMedPubMedCentral

50.

Le QT, Fu KK, Kaplan M, Terris DJ, Fee WE, Goffinet DR. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems. Cancer. 1999;86(9):1700–11.CrossRef

51.

Mierzwa ML, Nyati MK, Morgan MA, Lawrence TS. Recent advances in combined modality therapy. Oncologist. 2010;15(4):372–81. https://doi.org/10.1634/theoncologist.2009-S105.CrossRefPubMedPubMedCentral

52.

•• Robin TP, Jones BL, Gordon OM, Phan A, Abbott D, McDermott JD, et al. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer. 2017;123(16):3040–9. https://doi.org/10.1002/cncr.30686 Recent retrospective analysis of data obtained from National Cancer Data Base of treatment outcomes for over 11,000 patients with sinonasal malignances.CrossRefPubMedPubMedCentral

53.

Rosen A, Vokes EE, Scher N, Haraf D, Weichselbaum RR, Panje WR. Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993;119(7):743–6. https://doi.org/10.1001/archotol.1993.01880190039008.CrossRefPubMed

54.

• Pare A, Blanchard P, Rosellini S, Auperin A, Gorphe P, Casiraghi O, et al. Outcomes of multimodal management for sinonasal squamous cell carcinoma. J Craniomaxillofac Surg. 2017;45(8):1124–32. https://doi.org/10.1016/j.jcms.2017.05.006 Single institutional data from France suggesting multimodal therapy combining neoadjuvant chemotherapy followed by wide resection and adjuvant radiation therapy seems to provide promising results in management of SCC SNC.CrossRefPubMed

55.

Porceddu S, Martin J, Shanker G, Weih L, Russell C, Rischin D, et al. Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck. 2004;26(4):322–30. https://doi.org/10.1002/hed.10388.CrossRefPubMed

56.

Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A. Prognostic factors in sinonasal tumors involving the anterior skull base. Head Neck. 2004;26(2):136–44. https://doi.org/10.1002/hed.10358.CrossRefPubMed

57.

Bossi P, Perrone F, Miceli R, Cantu G, Mariani L, Orlandi E, et al. Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. Oral Oncol. 2013;49(5):413–9. https://doi.org/10.1016/j.oraloncology.2012.12.011.CrossRefPubMed

58.

Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol. 2004;22(24):4901–6. https://doi.org/10.1200/jco.2004.05.071.CrossRefPubMed

59.

Reiersen DA, Pahilan ME, Devaiah AK. Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg. 2012;147(1):7–14. https://doi.org/10.1177/0194599812440932.CrossRefPubMed

60.

Castelnuovo P, Turri-Zanoni M, Battaglia P, Antognoni P, Bossi P, Locatelli D. Sinonasal malignancies of anterior skull base: histology-driven treatment strategies. Otolaryngol Clin N Am. 2016;49(1):183–200. https://doi.org/10.1016/j.otc.2015.09.012.CrossRef

61.

Bell D, Hanna EY. Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther. 2013;13(3):285–96. https://doi.org/10.1586/era.13.1.CrossRefPubMed

62.

Mourad WF, Hauerstock D, Shourbaji RA, Hu KS, Culliney B, Li Z, et al. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol. 2013;36(6):584–8. https://doi.org/10.1097/COC.0b013e31825eb3a5.CrossRefPubMed

63.

Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112(8 Pt 1):1450–5. https://doi.org/10.1097/00005537-200208000-00023.CrossRefPubMed

64.

Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504–12. https://doi.org/10.1200/jco.18.00353.CrossRefPubMedPubMedCentral

65.

Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, et al. Management of paranasal sinus malignancy. Curr Treat Options in Oncol. 2005;6(1):3–18.CrossRef

66.

Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, et al. Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013;19(16):4488–98. https://doi.org/10.1158/1078-0432.Ccr-13-0739.CrossRefPubMed

67.

Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327–34. https://doi.org/10.1001/jama.2011.746.CrossRefPubMedPubMedCentral

68.

Valsecchi ME, Sato T. The potential role of sunitinib targeting melanomas. Expert Opin Investig Drugs. 2013;22(11):1473–83. https://doi.org/10.1517/13543784.2013.837449.CrossRefPubMed

69.

Ganti A, Raman A, Shay A, Kuhar HN, Auger SR, Patel T, et al. Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis. Laryngoscope. 2019. https://doi.org/10.1002/lary.27995.CrossRef

70.

Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 1992;102(8):843–9. https://doi.org/10.1288/00005537-199208000-00001.CrossRefPubMed

71.

Eich HT, Hero B, Staar S, Micke O, Seegenschmiedt H, Mattke A, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol. 2003;179(4):233–40. https://doi.org/10.1007/s00066-003-1089-x.CrossRefPubMed

72.

Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, et al. Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg. 2006;132(2):134–8. https://doi.org/10.1001/archotol.132.2.134.CrossRefPubMed

73.

Callender TA, Weber RS, Janjan N, Benjamin R, Zaher M, Wolf P, et al. Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg. 1995;112(2):252–7. https://doi.org/10.1016/s0194-59989570246-6.CrossRefPubMed

74.

Edmonson JH. Chemotherapeutic approaches to soft tissue sarcomas. Semin Surg Oncol. 1994;10(5):357–63.CrossRef

75.

Khan MN, Husain Q, Kanumuri VV, Boghani Z, Patel CR, Liu JK, et al. Management of sinonasal chondrosarcoma: a systematic review of 161 patients. Int Forum Allergy Rhinol. 2013;3(8):670–7. https://doi.org/10.1002/alr.21162.CrossRefPubMed

76.

van den Berg H, Schreuder WH, de Lange J. Osteosarcoma: a comparison of jaw versus nonjaw localizations and review of the literature. Sarcoma. 2013;2013:316123. https://doi.org/10.1155/2013/316123.CrossRefPubMedPubMedCentral

77.

Scangas GA, Eloy JA, Lin DT. The role of chemotherapy in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin N Am. 2017;50(2):433–41. https://doi.org/10.1016/j.otc.2016.12.015.CrossRef

Title: Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment
Authors: Mayur D. Mody, MD
Nabil F. Saba, MD, FACP
Publication date: 01-01-2020
Publisher: Springer US
Keywords: Systemic Therapy
Cytostatic Therapy
Published in: Current Treatment Options in Oncology / Issue 1/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-019-0696-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 1/2020

Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy

Epidermal Growth Factor Receptor’s Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies

Prognosticating for Adult Patients With Advanced Incurable Cancer: a Needed Oncologist Skill

The Microbiota in Hematologic Malignancies

Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy

Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer